Rakuten Medical
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Rakuten Medical sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Rakuten Medical: 5 sponsored US clinical trials, 1 recruiting.
Rakuten Medical sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Head and Neck Squamous Cell Carcinoma, with 2 trials.
Upper-quartile sponsor footprint
Rakuten Medical sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
NCT05182866
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
NCT04305795
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
NCT03769506
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
NCT02422979
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
What is open in the Rakuten Medical pipeline
1 recruiting of 5 indexed (20% open); 1 completed (20%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Recurrent Head and Neck Squamous Cell Carcinoma (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rakuten Medical: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Rakuten Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Rakuten Medical page
5 registered trials is a research-attention snapshot, not an endorsement of Rakuten Medical or any single study.
- 1 of Rakuten Medical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Head and Neck Squamous Cell Carcinoma is the condition Rakuten Medical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Head and Neck Squamous Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rakuten Medical pipeline card: 5 registered trials from official public datasets.Report a data error.